Progress made with mRNA vaccine technology marking an historic achievement and a significant milestone for our partnership with Arcturus Therapeutics, Japan’s MHLW approved KOSTAIVE®, the world’s first sa-mRNA COVID-19 vaccine for initial vaccination and booster for adults 18 years and older. Strengthening existing partnerships including joining Brandon Capitol’s new BioCatalyst Fund 6, extending the partnership with BaseLaunch and joining Biopôle SA’s R&D campus in Lausanne. Sustainability Focused on innovative products, innovative manufacturing processes and protecting the health of patients and the general public. • Set new initial goals in support of performance across CSL’s sustainability focus areas that seek to enable a healthier world, also embedding health equity and empowerment and inclusion and belonging as part of CSL’s strategic focus areas. • Ranked among the best large employers in America by Forbes magazine and named to Forbes Global 2000; also among Work180 Top Workplaces for Women in Australia and Prosple Top 100 Graduate Employers in Australia. • Continue to advance best-in-class plasma donor experience with the rollout of the Rika Plasma Donation System™, Project REACH and individualised nomograms. Research and development Evolving our sustainability strategy, creating a foundation for success and shared value creation through 2030 and beyond. • To ensure a robust and diverse innovation pipeline based on a foundation of scientific excellence, CSL continues to strengthen its therapeutic area focus underpinned with robust technical development platforms. • HEMGENIX®, the first FDA-approved gene therapy for adults with haemophilia B, won Best Product for Rare/ Orphan Diseases at the 2023 Prix Galien USA Award. 87 product registrations or new indications in 28 countries 74.8% Employee engagement index 2024 13 clinical trial results were published on an ICMJE‑recognised public clinical trial registry US$15.7m in product access support 7clinical trials had a first patient enrolled during the year 90% Donors willing to refer a friend 56% women at the Board level 12% on 2023 2024 2023 44% 59% women across CSL Equal to 2023 2024 2023 59% 7
RkJQdWJsaXNoZXIy MjE2NDg3